NatWest Group’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

NatWest Group’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,940	Closed	-$201K	–	630
2014 Q1	$201K	Buy	+1,940	New	+$199K	0.01%	532
2013 Q4	–	Sell	-8,654	Closed	-$579K	–	994
2013 Q3	$579K	Buy	+8,654	New	+$596K	0.02%	647

Other funds holding SLXP

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NatWest Group's SLXP Position: Q2 2014 in Review

NatWest Group sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2014, closing a stake of 1,940 shares — an estimated $201K sold.

NatWest Group first reported a position in SLXP in Q3 2013 and held it in 2 quarters. The position peaked at $579K in Q3 2013. 308 funds tracked by Wall St. Rank hold SLXP as of Q2 2014.

NatWest Group reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2014 after selling out during the quarter.
NatWest Group sold 1,940 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2014, an estimated $201K.
NatWest Group first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2013 and held it in 2 quarters.
NatWest Group's SALIX PHARMACEUTICALS LTD DEL position peaked at $579K in Q3 2013.
308 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2014.

Based on NatWest Group's 13F filing for Q2 2014, filed 13 Aug 2014.